Literature DB >> 9628

The properties of beta-adrenoceptor antagonists.

R G Shanks.   

Abstract

After the clinical studies with pronethalol and propranolol confirmed Black's hypothesis that drugs which block beta-adrenoceptors were of value in the treatment of patients with angina pectoris and cardiac arrhythmias, other compounds have been described which block beta-adrenoceptors. Detailed pharmacological studies with propranolol and comparison of its properties with those of other beta-adrenoceptor blocking drugs have indicated that these drugs may possess properties in addition to their effect in blocking beta-adrenoceptors. These properties have been termed intrinsic sympathomimetic activity, membrane stabilizing activity and cardioselectivity. These properties have all been described in detailed observations in laboratory animals but not to the same extent in normal man or in patients. It appears that the therapeutic effectiveness of these drugs results from their beta-adrenoceptor blocking activity and that intrinsic sympathomimetic activity and membrane stabilizing activity do not contribute to the effects of these drugs in patients, although cardioselectivity may be of value in some patients.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 9628

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  11 in total

1.  Comparison of disposition and effect of timolol and propranolol on exercise tachycardia.

Authors:  T Ishizaki; K Tawara
Journal:  Eur J Clin Pharmacol       Date:  1978-11-09       Impact factor: 2.953

2.  Evaluation of two oxprenolol oral osmotic (OROS) delivery systems in patients with essential hypertension.

Authors:  G T McInnes; M J Brodie
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

Review 3.  The medical treatment of angina pectoris.

Authors:  D A Chamberlain
Journal:  Br Heart J       Date:  1987-12

Review 4.  Formulary considerations in selection of beta-blockers.

Authors:  K C Yedinak
Journal:  Pharmacoeconomics       Date:  1993-08       Impact factor: 4.981

5.  Comparison of the efficacy and pharmacokinetics of conventional propranolol and a long acting preparation of propranolol.

Authors:  W J Leahey; J D Neill; M P Varma; R G Shanks
Journal:  Br J Clin Pharmacol       Date:  1980-01       Impact factor: 4.335

6.  Long-term haloperidol-treatment of mice: a change in beta-adrenergic receptor responsiveness.

Authors:  R Dunstan; D M Jackson
Journal:  J Neural Transm       Date:  1979       Impact factor: 3.575

Review 7.  Sotalol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use.

Authors:  B N Singh; P Deedwania; K Nademanee; A Ward; E M Sorkin
Journal:  Drugs       Date:  1987-09       Impact factor: 9.546

8.  Observation on the efficacy and pharmacokinetics of betaxolol (SL 75212), a cardioselective beta-adrenoceptor blocking drug.

Authors:  K Balnave; J D Neill; C J Russell; D W Harron; W J Leahey; R Wilson; R G Shanks
Journal:  Br J Clin Pharmacol       Date:  1981-02       Impact factor: 4.335

9.  Low-dose propranolol for the protection of the left ventricle from ischaemic damage.

Authors:  A H Brown; B L Krause; G M Morritt
Journal:  Thorax       Date:  1981-11       Impact factor: 9.139

10.  The assessment in man of the beta-adrenoceptor blocking activity and cardioselectivity of H-I 42 BS, a long acting beta-adrenoceptor blocking drug.

Authors:  T H Pringle; A H Deering; M G Scott; D W Harron; R G Shanks
Journal:  Br J Clin Pharmacol       Date:  1987-04       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.